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Abstract
Background: After an initial attack of biliary pancreatitis, cholecystectomy minimizes the risk of recurrent biliary
pancreatitis and other gallstone-related complications. Guidelines advocate performing cholecystectomy within 2 to
4 weeks after discharge for mild biliary pancreatitis. During this waiting period, the patient is at risk of recurrent
biliary events. In current clinical practice, surgeons usually postpone cholecystectomy for 6 weeks due to a
perceived risk of a more difficult dissection in the early days following pancreatitis and for logistical reasons. We
hypothesize that early laparoscopic cholecystectomy minimizes the risk of recurrent biliary pancreatitis or other
complications of gallstone disease in patients with mild biliary pancreatitis without increasing the difficulty of
dissection and the surgical complication rate compared with interval laparoscopic cholecystectomy.
Methods/Design: PONCHO is a randomized controlled, parallel-group, assessor-blinded, superiority multicenter trial.
Patients are randomly allocated to undergo early laparoscopic cholecystectomy, within 72 hours after
randomization, or interval laparoscopic cholecystectomy, 25 to 30 days after randomization. During a 30-month
period, 266 patients will be enrolled from 18 hospitals of the Dutch Pancreatitis Study Group. The primary endpoint
is a composite endpoint of mortality and acute re-admissions for biliary events (that is, recurrent biliary pancreatitis,
acute cholecystitis, symptomatic/obstructive choledocholithiasis requiring endoscopic retrograde
cholangiopancreaticography including cholangitis (with/without endoscopic sphincterotomy), and uncomplicated
biliary colics) occurring within 6 months following randomization. Secondary endpoints include the individual
endpoints of the composite endpoint, surgical and other complications, technical difficulty of cholecystectomy and
costs.
Discussion: The PONCHO trial is designed to show that early laparoscopic cholecystectomy (within 72 hours)
reduces the combined endpoint of mortality and re-admissions for biliary events as compared with interval
laparoscopic cholecystectomy (between 25 and 30 days) after recovery of a first episode of mild biliary pancreatitis.
(Continued on next page)
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Background
Acute pancreatitis is a major healthcare problem. The
disease is the third most common gastrointestinal reason
for acute hospital admission, carrying a mortality rate of
5% with a total annual cost of $2.2 billion in the USA
alone [1,2]. In most western countries approximately 30
to 55% of cases are caused by gallstones or sludge, re-
ferred to as biliary pancreatitis [3]. After biliary pancrea-
titis, patients may experience a recurrent episode of
biliary pancreatitis or other biliary events, such as acute
cholecystitis, common bile duct obstruction, cholangitis
or biliary colics [4,5]. In order to prevent these recurrent
biliary events, international guidelines advise performing
cholecystectomy or endoscopic sphincterotomy (ES)
after biliary pancreatitis [6,7]. Failure to provide defini-
tive treatment exposes the patient to (potentially fatal)
risks of biliary diseases [8].
The timing of cholecystectomy in patients with clinic-
ally severe pancreatitis, with local complications such as
pancreatic necrosis and organ failure, is deliberately
delayed until local complications have resolved, typically
after some 6 weeks [9].
In patients with mild pancreatitis, international guide-
lines advise cholecystectomy directly after recovery or in
the first 2 to 4 weeks after discharge for mild biliary pan-
creatitis [4,6,7,10,11]. However, there is no consensus on
the ideal moment of cholecystectomy. Audits from
Germany, the UK, the USA and Italy report that the ma-
jority of specialists perform an interval cholecystectomy
6 to 12 weeks after discharge, due to uncertainty about
the efficacy and safety of an early cholecystectomy and
for logistical reasons [12-15]. In a nationwide study in
the Netherlands, we demonstrated that three-quarters of
the patients admitted with mild biliary pancreatitis
underwent cholecystectomy a median of 6 weeks after
discharge [16]. Comparable results were found in a sys-
tematic review by our group where over 50% of patients
underwent cholecystectomy at least 6 weeks after dis-
charge [17].
Several nonrandomized studies in patients with mild
biliary pancreatitis suggested that early cholecystectomy,
as compared with interval cholecystectomy, prevents re-
current biliary pancreatitis or other complications of
gallstone disease, without adding risks due to a more dif-
ficult surgical dissection in the early days following pan-
creatitis [16,18]. Because the current literature may be
flawed by selection bias, a randomized study is needed
to confirm that early cholecystectomy is indeed both su-
perior to interval cholecystectomy and safe. The aim of
this study is to investigate whether early laparoscopic
cholecystectomy, within 72 hours after recovery of a first
episode of mild biliary pancreatitis, as compared with
interval laparoscopic cholecystectomy, 25 to 30 days
after recovery, reduces mortality and acute re-admissions
for biliary events.
Methods/Design
Design
The PONCHO trial is a randomized controlled, parallel-
group, assessor-blinded, superiority multicenter trial.
Patients will be randomly allocated to receive early lap-
aroscopic cholecystectomy, within 72 hours after
randomization, or interval laparoscopic cholecystectomy,
25 to 30 days after randomization.
Primary endpoint
The primary endpoint is a composite endpoint of mor-
tality and acute re-admissions for biliary events (that is,
recurrent biliary pancreatitis, acute cholecystitis, symp-
tomatic/obstructive choledocholithiasis requiring endo-
scopic retrograde cholangiopancreaticography (ERCP)
including cholangitis (with/without ES), and uncompli-
cated biliary colics; see Table 1 for definitions) occurring
within 6 months following randomization.
Secondary endpoints
We hypothesize that early laparoscopic cholecystectomy
is both effective and safe and therefore included the fol-
lowing secondary endpoints to assess such an effect: indi-
vidual endpoints of the composite endpoint; cholangitis
(Table 2); number of biliary colics registered in patient
diary; difficulty of cholecystectomy (scored by visual
analog scale 0 to 10; 5 being averagely difficult); conver-
sion to open cholecystectomy (measure of technical dif-
ficulty); total length of hospital stay; need for ICU
admission and total length of ICU stay; and total direct
and indirect costs.
Safety endpoints
The safety endpoints are: biliary leakage, Amsterdam
types A to D (Table 2) [23]; need for additional surgical,
radiological or endoscopic interventions [23]; other com-
plications requiring treatment (that is, bacteremia or
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pneumonia); bleeding requiring reoperation or blood
transfusion; and new-onset organ failure (Table 2).
Study population
All adult patients admitted with a first episode of biliary
acute pancreatitis to one of the 18 participating hospitals
of the Dutch Pancreatitis Study Group (listed in Authors’
information) will be assessed for eligibility during their
hospital admission. Potentially eligible patients are fol-
lowed until eligibility is established 1 or 2 days before
discharge from the hospital. If patients are classified as
having mild biliary pancreatitis and fulfill all inclusion
and exclusion criteria they are randomized (with a 1:1
ratio and stratified for hospital and ES) to undergo early
Table 1 Primary endpoint: definitions of biliary events
Biliary event Definition
Biliary pancreatitis Diagnosis of acute pancreatitis if at least two of the three following features are present [19]:
1. Upper abdominal pain;
2. Serum lipase or amylase levels above three times the upper level of normal;
3. Characteristic findings of acute pancreatitis on cross-sectional abdominal imaging.
Biliary pancreatitis if one of the following definitions is present [20]:
1. Gallstones and/or sludge diagnosed on imaging (transabdominal or endoscopic ultrasound or computed tomography);
2. In the absence of gallstones and/or sludge, a dilated common bile duct on ultrasound (>8 mm in patients ≤75 years old
or >10 mm in patients >75 years old);
3. The following laboratory abnormality: alanine aminotransferase (ALAT) level >2 times higher than normal values,
with ALAT >aspartate aminotransferase.
Acute cholecystitis Defined according to the 2007 Tokyo classification, grade I to III [21,22].
A. Local signs of inflammation:
1) Murphy’s sign;
2) RUQ mass/pain/tenderness.
B. Systemic signs of inflammation:
1) Fever;
2) Elevated C-reactive protein;
3) Elevated white blood cell count.
C. Imaging findings characteristic of acute cholecystitis
Definite diagnosis
1) One item in A and one item in B are positive;
2) C confirms the diagnosis when acute cholecystitis is suspected clinically.
Biliary colic Upper abdominal pain (either right upper quadrant or epigastric pain) lasting at least 30 minutes, according to the
Rome criteria [22].
Table 2 Secondary endpoint: definitions
Biliary event Definition
Cholangitis All of the following features (as previously defined) [20]:
1) Serum total bilirubin level >40 μmol/l (>2.3 mg/dl) and/or dilated common bile duct (>6 mm) on transabdominal
or endoscopic ultrasound or computed tomography;
2) Temperature >38.5°C.
Organ failure Failure of one or more of the following organ systems [19]:
1) Respiratory: PaO2 ≤60 mmHg or need for mechanical ventilation;
2) Cardiovascular: systolic blood pressure <90 mmHg or need for catecholamine support;
3) Renal: creatinine level >177 μmol/l after rehydration or need for hemofiltration or hemodialysis
(not including pre-existent renal failure).
Biliary leakage Defined according to the Amsterdam criteria [23]:
Type A: cystic duct leaks or leakage from aberrant or peripheral hepatic radicals;
Type B: major bile duct leaks with or without concomitant biliary strictures;
Type C: bile duct strictures without bile leakage;
Type D: complete transection of the duct with or without excision of some portion of the bile duct.
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laparoscopic cholecystectomy or interval laparoscopic
cholecystectomy (Figure 1).
Inclusion criteria
Inclusion criteria are: age ≥18 years; diagnosis of acute
pancreatitis (at least two of the three following features
present [19]: upper abdominal pain; serum lipase or
amylase levels above three times the upper level of
normal; and characteristic findings of acute pancreatitis
on cross-sectional abdominal imaging); mild pancreatitis
(fulfilling both [19]: no pancreatic necrosis and/or peri-
pancreatic collections; and no persistent (> 48 hours)
organ failure (Table 2)); and biliary pancreatitis (any of
the following three definitions [20,25-29]: gallstones
and/or sludge diagnosed on imaging (transabdominal or
endoscopic ultrasound or computed tomography); in the
absence of gallstones and/or sludge, a dilated common
bile duct on ultrasound (>8 mm in patients ≤75 years old
or >10 mm in patients >75 years old); and alanine amino-
transferase level >2 times higher than normal values,
with serum alanine aminotransferase levels >aspartate
aminotransferase level); and written informed consent.
Exclusion criteria
Exclusion criteria are: American Society of Anesthesiolo-
gists (ASA) III patients >75 years old; ASA IV and V
patients; patients with ongoing alcohol abuse or chronic
pancreatitis (males >3 units per day, females >2 units
per day) [30]; or pregnancy.
Time of randomization
After eligibility has been confirmed and written
informed consent has been obtained, randomization will
take place when the following five discharge criteria are
met: the treating physician anticipates that the patient
can be discharged within 1 or 2 days; no need for opioid
analgesics; declining C-reactive protein levels and <100
mg/l; no evidence of local or systemic complications (for
example, no fever); and the patient has resumed oral
intake.
Randomization
Randomization is possible 24 hours per day, 7 days per
week and is performed centrally by the study coordin-
ator using an Internet randomization module (Clinical
Research Unit, Academic Medical Center, Amsterdam,
the Netherlands). Randomization is stratified according
to whether ES is performed and according to hospital.
Randomization is balanced for ES because ES has a
protective effect on the occurrence of recurrent biliary
pancreatitis and common bile duct obstruction [31].
This allows for subgroup analysis with or without ES.
Randomization is balanced per hospital as treatment
strategies, such as the use of intraoperative cholangiog-
raphy, indication for enteral feeding and endoscopic
sphincterotomy, may differ between hospitals.
Permuted-block randomization with varying block
size is used and block size is concealed to all investi-
gators involved in this study. Using this method it is
impossible for investigators to predict the allocation of
Assessed for eligibility (n=…)
Randomised (n=266)
Allocated to early laparoscopic
cholecystectomy (n=133)
Received allocated intervention (n=…)
Lost to follow-up (give reasons) (n=…)
Discontinued intervention (give reasons)
(n=…)
Analysed (n=…):
Excluded from analysis (give reasons)
(n=…)
Excluded
Not meeting inclusion criteria (n=…)
Declined to participate (n=…)
Other reasons (n=…)
Allocated to late laparoscopic
cholecystectomy (n=133)
Received allocated intervention (n=…)
Lost to follow-up (give reasons) (n=…)
Discontinued intervention (give reasons)
(n=…)
Analysed (n=…):
Excluded from analysis (give reasons)
(n=…)
Figure 1 Flow of participants in the PONCHO trial. According to CONSORT [24].
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trial participants. Concealing the allocation for investi-
gators or trial participants is unfeasible due to the na-
ture of this trial, because trial participants need to be
scheduled for an early or interval cholecystectomy.
Treatment protocol
Group A received early laparoscopic cholecystectomy,
within 72 hours after randomization (Figure 2).
As can be seen in the time of randomization criteria,
patients will be randomized 1 or 2 days prior to dis-
charge in an attempt to prevent prolonged hospital stay
due to a waiting time for cholecystectomy.
Group B received interval laparoscopic cholecystec-
tomy, 25 to 30 days after randomization (Figure 2).
Surgical details and quality control
Laparoscopic cholecystectomy will be performed accord-
ing to the guidelines of the Dutch Society of Surgery,
which include the critical view of safety technique [32-
34]. Patients are operated on by, or under the direct
supervision of, a laparoscopically trained surgeon with
>100 laparoscopic procedures performed in the previous
5 years. There has to be supervision during the entire
procedure, from incision to skin closure.
Single port cholecystectomy will not be performed in
this study because there is currently limited experience
with this procedure in the Netherlands. If the treating
physician decides to perform a primary open cholecyst-
ectomy (laparotomy or minilaparotomy), this is allowed
in the trial.
Centers may only participate if they intend to randomize
at least five patients in the study and are able to perform
cholecystectomy <72 hours after randomization.
Given the excellent availability of ERCP/ES in the
Netherlands and the lack of experience with intra-
operative cholangiography, it is not mandatory to per-
form an intraoperative cholangiography and, if possible,
transcystic stone extraction. In centers with sufficient
experience, this technique is allowed. However, laparo-
scopic choledochal incision and exploration is not allowed
as there is insufficient experience with this technique and
it is likely to be associated with more morbidity than
ERCP/ES. The following data regarding intraoperative
cholangiography will be collected: incidence of choledo-
cholithiasis, percentage stones retrieved transcystically,
percentage bile duct injury, additional time required, and
perceived difficulty (visual analog scale 0 to 10, 5 being
averagely difficult).
Diagnosing and treating biliary pancreatitis
For imaging, in the first 24 hours of admission all
patients will undergo an abdominal ultrasound aimed at
detecting gallstones and/or sludge in the gallbladder and
at determining the diameter of the common bile duct.
Contrast-enhanced computed tomography (CECT) is
only performed if the diagnosis for acute pancreatitis is
unclear. CECT performed in the first 72 hours of acute
pancreatitis cannot rule out necrotizing pancreatitis.
Because PONCHO is a pragmatic trial and in current
clinical practice CECT is not performed routinely in
Eligible patients with mild biliary
pancreatitis
Randomization
Early laparoscopic cholecystectomy
< 72 hours after randomization
Interval laparoscopic cholecystectomy
25 – 30 days after randomization
All discharge criteria are met:
1) The treating physician anticipates that the
patient can be discharged within 1 - 2 days;
2) No need of opioid analgesics;
3) Declining CRP levels and < 100 U/L mg/
dL;
4) No evidence of local or systemic
complications (e.g. no fever);
5) The patient has resumed oral intake.
Informed consent
Figure 2 PONCHO overview of eligibility and group allocation.
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these patients, CECT is not scheduled for study pur-
poses. CECT will be performed whenever dictated by
clinical circumstances based on the judgment of the
treating physicians. When the patient’s condition does
not improve after 1 week of hospital admission, CECT is
performed to visualize the pancreas and abdomen.
ERCP/ES is performed when indicated by the treating
physician.
Ursodeoxycholic acid therapy is not recommended
after discharge since a recent Dutch randomized multi-
center trial showed that this treatment is not effective in
preventing recurrent colics and complications [35].
Data collection and follow-up
There will be telephone follow-up contacts at 3 and 6
months after randomization. When patients are re-
admitted to the hospital they are requested to contact
the study coordinator. Patients are further asked to
register biliary colics during the follow-up period in a
gallstone diary. At 6 and 12 weeks after randomization,
patients will be asked to complete the Health and
Labour questionnaire [36]. Clinical data with regard to
baseline characteristics and outcomes will be collected
during hospital admission using a case record form. The
case record form will be filled out by the local treating
physicians, the study coordinator or the study nurse.
The study coordinator and the study nurse are allowed
to correct wrongly entered data (such as miscalculated
patient age or miscalculated disease severity scores). The
case record forms will be checked with source data.
Only study group personnel will have access to the
unblinded source data.
Safety
An independent Data and Safety Monitoring Committee
(DSMC) will evaluate the progress of the trial and will
examine safety variables. Every 30 patients, individua-
lized patient description charts including unblinded
safety parameters will be presented to the DSMC. In
addition to the safety endpoints, death and (serious) ad-
verse events, the incidence of biliary leakage, Amster-
dam type D [23], will be of special interest. Extra
monitoring of this severe complication is clinically im-
portant. The incidence of bile duct injury (Amsterdam
types A to D) has a range between 0.16 and 1.5% in the
Netherlands [21].
After full explanation of the data presented by the
investigators, the members of the DSMC will discuss
the consequences of the data presented in the absence
of the investigators. Adverse events are defined as ‘any
undesirable experience occurring to a subject during a
clinical trial, whether or not considered related to the
intervention’ (that is, early cholecystectomy). All involved
physicians will repetitively be asked to report any potential
adverse events. These adverse events will be listed and
discussed by the DSMC. The outcome of the meeting of
the DSMC will then be discussed with the trial steering
committee. The outcome will also be sent to the Institu-
tional Review Board of the Radboud University Nijmegen
Medical Centre. All possible severe adverse events will
be reported to the Central Committee on Research in-
volving Human Subjects (Centrale Commissie Mensge-
bonden Onderzoek) and the Institutional Review Board
using the online module [37].
Ethics
The study will be performed in accordance with the dec-
laration of Helsinki and the Dutch Wet Medisch-
wetenschappelijk Onderzoek met Mensen (Medical Re-
search Involving Human Subjects Act). The Institutional
Review Board of the Radboud University Nijmegen
Medical Centre approved the protocol on 22 July 2010.
Secondary approval was sought from all local ethics
committees. Informed consent will be obtained from
each participating patient in oral and written form prior
to randomization. The PONCHO trial is registered in
the ISRCTN register with identification number
ISRCTN72764151.
After approval of the protocol, three amendments
were approved by the ethics board. These amendments
followed new regulations in the Netherlands for the
reporting of (serious) adverse events and minor protocol
changes. The content of the amendments are incorpo-
rated in this protocol.
Statistical aspects
Sample size calculation
The PONCHO trial is a superiority trial, hypothesizing a
reduction in the primary endpoint in favor of early
cholecystectomy compared with the current practice of
interval cholecystectomy. Data from our nationwide
retrospective analysis on timing of cholecystectomy after
mild biliary pancreatitis have been used to calculate the
sample size [16,38]. In this previous analysis, 6.0%
(n = 15) of 249 patients with mild biliary pancreatitis
were re-admitted within 4 weeks after discharge for
recurrent biliary problems prior to cholecystectomy,
including 5% recurrent biliary pancreatitis. Because this
study was retrospective it might have missed several re-
current complications (arbitrarily set at 20% missed
endpoints: 0.2×6% = 1.2%). Furthermore, some 1% of
patients may be re-admitted after cholecystectomy for
recurrent biliary events. This amounts to an expected
incidence of the primary endpoint in the interval laparo-
scopic cholecystectomy group of 8.2% (6.0 + 1.2 + 1.0).
This number is quite conservative compared with the
10% re-admission rate within 4 weeks after mild biliary
pancreatitis detected in our systematic review [17]. In
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the early laparoscopic cholecystectomy group, the re-
admission rate (primary endpoint) during 6 months
follow-up is set at 1% since, similar to the interval
group, patients may be re-admitted for recurrent biliary
events.
To demonstrate a reduction of the primary endpoint
from 8.2 to 1.0% with power 80% and two-sided alpha of
5%, 132 patients will have to be included in each study
group (PS Calculations, version 2.1.3; Vanderbilt Univer-
sity, Nashville, TN, USA). Taking a 0.5% (n = 2) loss to
follow-up (based on the previous PROPATRIA and
PANTER trials [38,39]), a total of 266 patients will have
to be randomized.
Descriptive statistics
For dichotomous data, frequencies will be presented.
Continuous data will be presented as mean and standard
deviation or median and interquartile range. Baseline
characteristics (all prior to randomization) are: age, sex,
body mass index, etiology of pancreatitis, ASA classifica-
tion, co-morbidity (that is, cardiovascular disease, pul-
monary disease, chronic renal insufficiency or diabetes),
predicted severity (Acute Physiology and Chronic Health
Evaluation II score, Imrie score and C-reactive protein),
time from onset of symptoms to randomization, and
time from onset of symptoms to cholecystectomy.
Analyses
All analyses will be by intention-to-treat, meaning that
all randomized patients are included in their initially
assigned study arm, regardless of adherence to study
protocol. There will be a blinded outcome assessment
after the last patient in the trial has completed the fol-
low-up. An adjudication committee blinded for treat-
ment allocation will evaluate each patient using the raw
data for the possible occurrence of the primary endpoint.
Disagreements will be resolved in a plenary consensus
meeting.
The primary endpoint will be compared between the
treatment groups and subsequent analyses are directed
at the secondary and safety endpoints. To compare the
safety and efficacy of both treatment strategies, all indi-
vidual endpoints of the combined primary, secondary
and safety endpoints will be taken together and com-
pared between both treatment groups.
Results are presented as risk ratios with corresponding
95% confidence intervals. Two-tailed P <0.05 is consid-
ered statistically significant with correction for multiple
testing. In the event of imbalance between the two treat-
ment groups a multivariable logistic regression will be
used to correct for possible confounders. A post-hoc ana-
lysis will compare cholecystectomies with and without
cholangiography.
Additional analyses
A predefined subgroup analysis will be performed on
patients with or without ES, per center and age (<75
years vs. >75 years). We will use logistic regression mod-
els to perform a formal test for interaction to assess
whether treatment effects differed significantly between
these subgroups.
The costs of both treatment strategies for the whole
follow-up period of 6 months will be compared. All
costs will be estimated based on the actual input in
terms of resource use, personnel and indirect costs from
loss of productivity due to sick leave (assessed by the
Health and Labour Questionnaire).
Premature termination of the study
In addition to assessing the safety of the patients in the
study, the DSMC will check for early proof of efficacy
during an interim analysis for benefit, which will be per-
formed halfway through the study. The Peto approach
will be followed, meaning that the study will only be
stopped for beneficial effects in the event of P <0.001
[40]. The trial will not be stopped for futility, because
this is the first randomized trial on this subject and
treatment policy worldwide will be influenced by the
results, regardless of the outcome.
If the DSMC suspects harm there will be a meeting
between the DSMC, the steering committee and an in-
dependent statistician. During this meeting there should
be a discussion about any potential causal relation be-
tween early cholecystectomy and harm based on the
current literature.
The trial will be prematurely terminated if, after 4
years of inclusion, the required number of patients has
not been reached, meaning a 60% delay in relation to the
planned inclusion period of 2.5 years (30 months). End-
points are not monitored sequentially.
Publication policy
All members of the steering committee and investigators
involved in the daily logistics of the trial will be men-
tioned as an author.
For others, co-authorship will be based on the inter-
national guidelines, with a maximum of one co-author
per participating site. Participating clinicians that do not
fulfill these criteria will be listed as a collaborator and
the journal will be asked to present the names of all col-
laborators to be listed in PubMed.
The order of authors will be based primarily on scien-
tific input and secondarily on the number of randomized
patients.
Discussion
The PONCHO trial is designed to answer the question
of whether early cholecystectomy leads to a reduction of
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re-admissions for biliary events in patients with a first
episode of mild biliary pancreatitis.
Several treatment guidelines state that cholecystectomy
should be performed in the first weeks after recovery
of mild biliary pancreatitis in order to minimize re-
admissions for biliary events [4,6,7,10,11,16]. In a sys-
tematic review we demonstrated that cholecystectomy
should probably be performed during index admission
because an early procedure was not associated with an
increased risk of complications whereas interval chole-
cystectomy (after median 40 days) was associated with a
biliary event recurrence rate of 18% [17]. In contrast to
this finding, several nationwide audits from the UK, the
USA, Germany and Italy have shown that most patients
undergo cholecystectomy weeks or even months after
discharge from the hospital for mild biliary pancreatitis
[12-15]. As long as the gallbladder is in situ, these
patients are at increased risk for re-admissions for biliary
events including a potentially fatal episode of acute pan-
creatitis or other biliary events.
Why are surgeons not routinely performing early lap-
aroscopic cholecystectomy after biliary pancreatitis? Early
cholecystectomy may have three potential downsides: a
technically more difficult and demanding procedure
potentially resulting in more complications; poorer patient
condition; and logistical hurdles.
Traditionally, early cholecystectomy has been sug-
gested to be technically more demanding than interval
cholecystectomy but data to support this statement are
lacking. Notably, a recent study found that early chole-
cystectomy was technically less demanding, which is in
keeping with the nature of peritoneal healing and adhe-
sion formation [41]. This concept is supported by a re-
cent retrospective study from India that focused on
difficult dissection during laparoscopic cholecystectomy
after mild biliary pancreatitis [18].
Traditionally, it is felt that patients should recover
fully from pancreatitis prior to cholecystectomy being
performed. However, the current study will only include
patients with mild pancreatitis who are fit to undergo
surgery. In contrast to severe pancreatitis, patients with
mild pancreatitis recover quickly, and are discharged
within 5 to 10 days after admission.
Problems with operating room capacity could arise
due to the need for semi-urgent (<72 hours) cholecystec-
tomy. In the participating centers, however, dedicated
operating room programs for semi-urgent surgery are
present, and hence no major problems with protocol
compliance are envisaged [41.
The only way to provide convincing, level I evidence
that early cholecystectomy is indeed superior to interval
cholecystectomy is to perform a randomized controlled
trial. A double-blinded controlled trial would be the
optimal design. However, due to the difference in timing
of cholecystectomy, blinding is not possible. To com-
pensate for this fact there will be a blinded outcome
assessment.
A time interval of 72 hours was chosen for the early
cholecystectomy group to provide a feasible time frame
for semi-urgent cholecystectomy by an experienced sur-
geon. The 25-day to 30-day interval (4 weeks) was
chosen as a trade-off between: the Dutch guideline that
advices cholecystectomy within 3 weeks after discharge,
and the data from our retrospective multicenter study
demonstrating that cholecystectomy is delayed for 6
weeks in current Dutch clinical practice [16].
The rationale for including ASA I and II older people/
octogenarians is because several series have demon-
strated that cholecystectomy is safe, even after ES, in
older patients [42,43]. Patients with severe pancreatitis
are excluded because this is considered an indication for
delayed cholecystectomy [9].
For the proper timing of randomization we have
chosen five discharge criteria that all have to be fulfilled
in order to only include patients who are fit to undergo
surgery and are without signs of severe pancreatitis. In
contrast to severe pancreatitis, patients with mild pan-
creatitis recover quickly and are typically discharged
within 5 to 10 days. There will be a variation in time
since the onset of pancreatitis and hospital admission
and between admission and discharge. This variation is
mainly caused by co-morbidity. Owing to the ran-
domization, there should be no relevant differences be-
tween both study arms.
The primary endpoint is a composite endpoint of
mortality and re-admissions for biliary events. This
composite endpoint was chosen because a study aimed at
demonstrating a reduction in mortality only would re-
quire an unrealistic large sample size. In addition, other
studies have shown that re-admissions for biliary events
have much impact on the prognosis of patients [16].
The PONCHO trial is a randomized controlled multi-
center trial designed to show a reduction in the compos-
ite primary endpoint of re-admissions for biliary events
and mortality following an early cholecystectomy com-
pared with an interval cholecystectomy in patients with
a first episode of mild biliary pancreatitis.
Trial status
The trial was registered in the ISRCTN register on
29 June 2010. The first patient was randomized on
22 December 2010. As of 21 October 2012, 172 patients
have been randomized and inclusion is on schedule.
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